As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

 3/15/24  Lurker Nancy                      3          Director²   2:9K   Alkermes plc                      Computershare Inc.       
  3/8/24  EyePoint Pharmaceuticals, Inc.    10-K       12/31/23  100:11M                                    Donnelley … Solutions/FA 
10/20/23  EyePoint Pharmaceuticals, Inc.    S-3                    5:779K                                   Donnelley … Solutions/FA 
10/20/23  EyePoint Pharmaceuticals, Inc.    S-8        10/20/23    4:118K                                   Donnelley … Solutions/FA 
 7/10/23  EyePoint Pharmaceuticals, Inc.    8-K:5,8,9   7/10/23   13:312K                                   Donnelley … Solutions/FA 
 5/18/23  Alimera Sciences Inc.             8-K:1,2,3,5 5/16/23   15:2.4M                                                            
 5/18/23  EyePoint Pharmaceuticals, Inc.    8-K:1,2,8,9 5/17/23   13:1.5M                                   Donnelley … Solutions/FA 
  5/4/23  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/23   80:9.4M                                   Donnelley … Solutions/FA 
 3/10/23  EyePoint Pharmaceuticals, Inc.    10-K       12/31/22  115:17M                                    Donnelley … Solutions/FA 
  1/6/23  EyePoint Pharmaceuticals, Inc.    8-K:2,5,8,9  1/3/23   16:775K                                   Donnelley … Solutions/FA 
 11/4/22  EyePoint Pharmaceuticals, Inc.    10-Q        9/30/22   80:11M                                    Donnelley … Solutions/FA 
  8/5/22  EyePoint Pharmaceuticals, Inc.    10-Q        6/30/22   85:11M                                    Donnelley … Solutions/FA 
  5/6/22  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/22   80:9.2M                                   ActiveDisclosure/FA      
 3/14/22‡ EyePoint Pharmaceuticals, Inc.    10-K       12/31/21  103:15M                                    ActiveDisclosure/FA      
 11/5/21  EyePoint Pharmaceuticals, Inc.    10-Q        9/30/21   78:9.4M                                   ActiveDisclosure/FA      
 11/1/21  EyePoint Pharmaceuticals, Inc.    8-K:5,9     11/1/21   12:370K                                   ActiveDisclosure/FA      
  8/6/21  EyePoint Pharmaceuticals, Inc.    S-3                    5:2.3M                                   Donnelley … Solutions/FA 
  8/6/21  EyePoint Pharmaceuticals, Inc.    10-Q        6/30/21   79:9.2M                                   ActiveDisclosure/FA      
  5/5/21  EyePoint Pharmaceuticals, Inc.    S-3/A                  2:226K                                   Donnelley … Solutions/FA 
  5/5/21  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/21   81:8.9M                                   ActiveDisclosure/FA      

____________
‡	A non-Insider-Ownership Filing that was accepted after the SEC “closed” at 5:30:00pm ET.  The legal “Filed As Of” date may be the next, or another, day.
¹	Filing/Form Types:
	3	Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 { The Filer is an Insider² of the Issuer }.
	8-K	Current Report — Form 8-K { Item 1: Business & Operations;  2: Financial Info;  3: Securities & Trading;  4: Accountants & Accounting;  5: Governance & Management;  6: Asset-Backed Securities;  7: Disclosures;  8: Events;  9: Financials }.
	10-K	Annual Report — Form 10-K.
	10-Q	Quarterly Report — Form 10-Q.
	S-3	Registration Statement – Securities for a Transaction — Form S-3.
	S-8	Registration Statement – Securities for an Employee Benefit Plan — Form S-8.
	/A	Amendment to, or Amended version of, a previous Filing of this Type.
²	Insider:  The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer.